Last reviewed · How we verify
HT-101
At a glance
| Generic name | HT-101 |
|---|---|
| Sponsor | Suzhou HepaThera Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection (PHASE2)
- A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection (PHASE1, PHASE2)
- This is a Phase 1 Study in Which Healthy Volunteers and Participants with Chronic HBV Infection Will Receive HT-101 or Placebo and Will Be Assessed for Safety, Tolerability, Pharmacokinetics (PK), and Antiviral Activity (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HT-101 CI brief — competitive landscape report
- HT-101 updates RSS · CI watch RSS
- Suzhou HepaThera Biotech Co., Ltd. portfolio CI